Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Authors:
- Vivien M. HsuVHVivien M. Hsu
- Ann J. ImpensAIAnn J. Impens
- Jennifer A. RothmanJRJennifer A. Rothman
- DEBORAH A. McCLOSKEYDMDEBORAH A. McCLOSKEY
- Julianne E. WilsonJWJulianne E. Wilson
- Kristine PhillipsKPKristine Phillips
- James R. SeiboldJSJames R. Seibold
- 15 September 2009
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (10) , 2264-2268
Abstract
Objective.: Raynaud’s phenomenon (RP) is an important clinical feature of systemic sclerosis (SSc) for which consistently effective therapies are lacking. The study was designed to assess the safety, tolerability, and efficacy of tadalafil, a selective, long acting type V cyclic GMP phosphodiesterase (PDE-5) inhibitor, in this clinical syndrome.Methods.: We performed a prospective, randomized, double-blind, placebo-controlled, crossover study comparing oral tadalafil at a fixed dose of 20 mg daily for a period of 4 weeks versus placebo in women with RP secondary to SSc.Results.: Thirty-nine subjects completed the study and were evaluable. There were no statistically significant differences in Raynaud Condition Score (RCS), frequency of RP episodes, or duration of RP episodes between treatment groups. Placebo response was a confounding factor. Tadalafil was well tolerated.Conclusion.: Tadalafil appears to be safe and well tolerated but lacks efficacy in comparison to placebo as a treatment for RP secondary to SSc.Keywords
This publication has 24 references indexed in Scilit:
- Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double‐blind, placebo‐controlled trial of the angiotensin‐converting enzyme inhibitor quinaprilArthritis & Rheumatism, 2007
- Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and FutureEuropean Urology, 2006
- Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsBritish Journal of Clinical Pharmacology, 2006
- Comparison of phosphodiesterase type 5 (PDE5) inhibitorsInternational Journal Of Clinical Practice, 2006
- Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertensionInternational Journal of Cardiology, 2006
- Understanding, assessing and treating Raynaudʼs phenomenonCurrent Opinion in HIV and AIDS, 2006
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionJACC, 2004
- Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosisArthritis & Rheumatism, 2001
- Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis & Rheumatism, 1999
- Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosisCochrane Database of Systematic Reviews, 1998